2024-11-12T09:55:37-05:00 2023-12-31 262064862 KOLLATH & ASSOCIATES CPA LLC 421 WATER ST STE 111 PRAIRIE DU SAC WI 53578 990 2023-01-01 871500208 WISCONSIN INSTITUTE FOR IMMUNE AND CELL THERAPY INC WISC 6087291450 726 POST ROAD MADISON WI 537134620 GARY A DAHL PRESIDENT 6087291450 2024-11-08 true true JULIE MILLER P00388780 6086440206 2024-11-08 2023 2024-10-15 13:58:12Z WIICT GARY A DAHL 726 POST ROAD MADISON WI 53713 633133 false X X 2021 WI THE ORGANIZATION'S PRIMARY EXEMPT PURPOSE IS TO ENGAGE IN THE CONTINUOUS ACTIVE CONDUCT OF MEDICAL RESEARCH IN CONJUNCTION WITH A HOSPITAL. 3 3 7 3 0 500000 500000 124653 8480 0 500000 633133 0 0 277345 565229 0 0 14870 145915 292215 711144 207785 -78011 265501 192955 24650 30115 240851 162840 X THE ORGANIZATION'S PRIMARY EXEMPT PURPOSE IS TO ENGAGE IN THE CONTINUOUS ACTIVE CONDUCT OF MEDICAL RESEARCH IN CONJUNCTION WITH A HOSPITAL. false false 599739 124563 IN 2023, WIICT CONTINUOUSLY CONDUCTED RESEARCH TO MAKE MULTIPLE MRNAS FOR ITS CLINICAL COLLABORATORS AT NIH CLINICAL CANCER CENTER IN BETHESDA, MD FOR EVALUATION AND USE IN CLINICAL RESEARCH AND IN PHASE 1 OR PHASE 1/2 HUMAN CLINICAL TRIALS. ONE OF THESE MRNAS ENCODES THE ACTIVE FORM OF A PROTEIN THAT IS INACTIVE OR LACKING IN ONE TYPE OF IMMUNE CELL OF PATIENTS HAVING A CERTAIN PRIMARY IMMUNE DEFICIENCY DISEASE (PID) DUE TO A MUTATION IN A GENE THAT IS REQUIRED TO KILL MICROBIAL OR VIRAL PATHOGENS WITH WHICH THE PATIENT CAN BECOME INFECTED (ON AVERAGE EVERY 2-3 YRS). THE TRIAL IS TO TEST WHETHER PATIENTS CAN BE TREATED BY TANSFECTING THE MRNA ENCODING THE ACTIVE MRNA INTO DEFECTIVE IMMUNE CELLS FROM THE PATIENTS BLOOD AND THEN REINTRODUCING THOSE TRANSFECTED CELLS INTO THE PATIENT. IN 2023, WIICT ALSO DESIGNED, MADE, AND CONDUCTED RESEARCH ON MULTIPLE MRNAS ENCODING GENE OR BASE-EDITING ENZYMES AND EVALUATED EACH MRNA WITH RESPECT TO YIELD, PURITY AND MULTIPLE QC ASSAY SPECIFICATIONS FOR CHEMICAL, BIOCHEMICAL, AND PHYSICAL PROPERTIES. THESE MRNAS WERE SENT TO WIICT'S COLLABORATORS AT NIH CLINICAL CANCER CENTER FOR EVALUATION OF THEIR EFFICIENCIES OF BOTH ON- TARGET CORRECTIONS OF TARGET GENE MUTATIONS AND OFF-TARGET ERRORS IN HUMAN CELLS AND ANIMAL MODELS TO GENERATE DATA TO SUPPORT INDS FOR PHASE 1 OR PHASE 1/2 HUMAN CLINICAL TRIALS. ADDITIONALLY, IT IS NOTED THAT 133,895 OF SERVICES AND USE OF MATERIALS, EQUIPMENT OR FACILITIES WAS DONATED IN-KIND IN CONNECTION WITH MEDICAL RESEARCH. 599739 true true false false false false false false false false false false false false false false false false false false false false false false false false false false false true false false false false false false false false false false false false false false false false false true 1 0 7 true false false false false false false false false false false false false false false X 3 3 true false false false false false false true true true false true true true true false false false false false X GARY A DAHL 6087291450 726 POST ROAD MADISON WI 53713 X GARY A DAHL PRESIDENT 1.00 X X 0 0 0 JEROME J JENDRISAK VP, SEC/TREA 1.00 X X 0 0 0 KIERAN COE DIRECTOR 1.00 X 0 0 0 JACOBA SLAGTER-JAGER HEAD OF MRNA 40.00 X 175785 0 0 175785 1 false true false 500000 500000 RESEARCH SERVICES AT COST 900999 124653 124653 124653 8480 8480 633133 124653 8480 464545 464545 63591 63591 37093 37093 3021 3021 34510 34510 480 480 80540 80540 6206 6206 SOFTWARE EXP-PROD-MFG 15132 15132 OTHER CONSULTING SERVICES 2500 2500 OFFICE SUPPLIES 2039 2039 TELEPHONE 1322 1322 165 165 711144 599739 111405 0 258524 57713 5000 133359 1977 1883 265501 192955 24650 30115 24650 30115 X 65000 65000 175851 97840 240851 162840 265501 192955 -78011 X false false false X NATIONAL INSTITUTES OF HEALTH CLINICAL CENTER BETHESDA MD RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false false false false false false false false false JACOBA SLAGTER-JAGER HEAD OF MRNA MFG 175785 175785 FORM 990, PAGE 2, PART III, LINE 4A IN 2023, WIICT CONTINUOUSLY CONDUCTED RESEARCH TO MAKE MULTIPLE MRNAS FOR ITS CLINICAL COLLABORATORS AT NIH CLINICAL CANCER CENTER IN BETHESDA, MD FOR EVALUATION AND USE IN CLINICAL RESEARCH AND IN PHASE 1 OR PHASE 1/2 HUMAN CLINICAL TRIALS. ONE OF THESE MRNAS ENCODES THE ACTIVE FORM OF A PROTEIN THAT IS INACTIVE OR LACKING IN ONE TYPE OF IMMUNE CELL OF PATIENTS HAVING A CERTAIN PRIMARY IMMUNE DEFICIENCY DISEASE (PID) DUE TO A MUTATION IN A GENE THAT IS REQUIRED TO KILL MICROBIAL OR VIRAL PATHOGENS WITH WHICH THE PATIENT CAN BECOME INFECTED (ON AVERAGE EVERY 2-3 YRS). THE TRIAL IS TO TEST WHETHER PATIENTS CAN BE TREATED BY TANSFECTING THE MRNA ENCODING THE ACTIVE MRNA INTO DEFECTIVE IMMUNE CELLS FROM THE PATIENTS BLOOD AND THEN REINTRODUCING THOSE TRANSFECTED CELLS INTO THE PATIENT. IN 2023, WIICT ALSO DESIGNED, MADE, AND CONDUCTED RESEARCH ON MULTIPLE MRNAS ENCODING GENE OR BASE-EDITING ENZYMES AND EVALUATED EACH MRNA WITH RESPECT TO YIELD, PURITY AND MULTIPLE QC ASSAY SPECIFICATIONS FOR CHEMICAL, BIOCHEMICAL, AND PHYSICAL PROPERTIES. THESE MRNAS WERE SENT TO WIICT'S COLLABORATORS AT NIH CLINICAL CANCER CENTER FOR EVALUATION OF THEIR EFFICIENCIES OF BOTH ON- TARGET CORRECTIONS OF TARGET GENE MUTATIONS AND OFF-TARGET ERRORS IN HUMAN CELLS AND ANIMAL MODELS TO GENERATE DATA TO SUPPORT INDS FOR PHASE 1 OR PHASE 1/2 HUMAN CLINICAL TRIALS. ADDITIONALLY, IT IS NOTED THAT 133,895 OF SERVICES AND USE OF MATERIALS, EQUIPMENT OR FACILITIES WAS DONATED IN-KIND IN CONNECTION WITH MEDICAL RESEARCH. FORM 990, PAGE 6, PART VI, LINE 2 JERRY JENDRISAK GARY DAHL JOINTLY OWN OTHER BUSINESSES FORM 990, PAGE 6, PART VI, LINE 9 KIERAN COE GODFREY KAHN ONE EAST MAIN ST STE500 MADISON, WI 53703 FORM 990, PAGE 6, PART VI, LINE 11B A COPY OF THE FORM 990 IS PROVIDED TO THE GOVERNING BODY PRIOR TO BEING FILED WITH THE INTERNAL REVENUE SERVICE FORM 990, PAGE 6, PART VI, LINE 12C THE ORGANIZATIONS WRITTEN CONFLICT OF INTEREST POLICY COVERS ANY "INTERESTED PERSON" COMPRISED OF ALL DIRECTORS OF THE BOARD OF DIRECTORS, OFFICERS, MEMBERS OF A COMMITTEE, OR STAFF MEMBERS OF THE ORGANIZATION. EVERY INTERESTED PERSON HAS A DUTY TO DISCLOSE POTENTIAL OR ACTUAL CONFLICT OF INTEREST EXISTS OCCUR AT ANY LEVEL WHERE THE PERSONAL, PROFESSIONAL, FINANCIAL INTEREST, OR FIDUCIARY DUTY OF THE INTERESTED PERSON IS OPPOSED TO THE ORGANIZATION, CONFLICTS WITH, OR INFLUENCES THE INTERESTED PERSON'S ACTIONS AND JUDGEMENT. THE BOARD OF DIRECTORS OR AN APPLICABLE COMMITTEE DESIGNATED BY THE BOARD WILL REVIEW AND DETERMINE WHETHER A POTENTIAL OR ACTUAL CONFLICT OF INTEREST EXISTS WITH RESPECT TO EACH INTERESTED PERSON. THE INTERESTED PERSONS IN WHICH A CONFLICT OF INTEREST EXISTS WILL BE PROHIBITED FROM PARTICIPATING IN THE DELIBERATIONS UNLESS TO ANSWER QUETIONS, AND WILL NEVER BE PRESENT WHEN DECISIONS ON CONFLICT RELATED TO A TRANSACTION ARE MADE. FORM 990, PAGE 6, PART VI, LINE 19 THE ORGANIZATION DOES NOT MAKE ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC.